Milestone Pharmaceuticals Inc
Officers & Directors
1. Joseph Oliveto, Chief Executive Officer and Director: Oliveto has over two decades of experience in the biopharmaceutical industry, with a focus on the development and commercialization of cardiovascular and metabolic therapies. Prior to Milestone Pharmaceuticals, he served as President and Chief Operating Officer of Chelsea Therapeutics (now merged with Helsinn Therapeutics). 2. Amit Hasija, Chief Financial Officer: Hasija serves as the principal financial officer and principal accounting officer, bringing extensive financial expertise to the company. 3. Robert J. Wills, Chairman of the Board: Wills has significant experience in board leadership roles within the biopharmaceutical sector. 4. Seth Fischer, Director: Fischer brings a wealth of experience in biopharmaceutical development and commercialization. 5. Debra K. Liebert, Director: Liebert holds extensive expertise in the strategic and operational aspects of the biopharmaceutical industry. 6. Richard Pasternak, Director: Pasternak has a strong background in medicine and biopharmaceutical development. 7. Michael Tomsicek, Director: Tomsicek is experienced in corporate governance and biopharmaceutical operations. 8. Lisa M. Giles, Director: Giles provides insights from her extensive experience in biopharmaceutical strategy and development.,
Milestone Pharmaceuticals Inc currently has 38 employees.
News about Milestone Pharmaceuticals Inc Key Personnel |
Navigating Challenges: Milestone Pharmaceuticals Confronts Financial Struggles Amid FDA Decision for EtripamilMilestone Pharmaceuticals Inc. is currently at a critical junction, as it grapples with significant financial challenges while preparing for a pivotal decision from the U.S. Food and Drug Administration (FDA) concerning its promising drug candidate, etripamil. The drug has been under scrutiny for its potential use in treating Paroxysmal Supraventricular Tachycardia (PSVT), a condition characterized by episodes of rapid heart rate. However, the FDA s recent issuance of a Complete Response Letter (CRL) for etripamil, which primarily focused on Chemistry, Manufacturing, and Controls (CMC) issues, has ra...
|
Investigation: A Path Forward for Milestone Pharmaceuticals Amid Financial StrugglesMilestone Pharmaceuticals Inc. has recently extended an invitation to investors to discuss its corporate outlook for 2025, coinciding with pivotal developments that may chart the company’s trajectory. With a major FDA decision on the horizon—a Prescription Drug User Fee Act (PDUFA) date set for March 27, 2025, regarding its innovative CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)—the stakes for Milestone are unprecedented. However, as financial indicators paint a challenging picture, key stakeholders must grapple with how the company intends to secure a bright future.For Milestone,...
|
|
